The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
Yıl: 2023 Cilt: 53 Sayı: 1 Sayfa Aralığı: 420 - 431 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5599 İndeks Tarihi: 30-03-2023
The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
Öz: Background and aim: The optimal sarcopenia measurement method in patients with a diagnosis of glioblastoma multiforme (GBM) is unknown. It has been found that temporal muscle thickness (TMT) may reflect sarcopenia and be associated with survival, but the relationship between temporal muscle area (TMA) and GBM prognosis has never been evaluated before. The primary outcome of the study was to evaluate the relationship between TMA/TMT and overall survival (OS) time in newly diagnosed GBM patients. Materials and methods: The data of patients who presented at the university hospital between January 2009 and January 2019 with a confirmed diagnosis of glioblastoma multiforme at the time of diagnosis were analyzed retrospectively. Temporal muscle thickness and TMA were measured retrospectively from preoperative MRIs of patients diagnosed with GBM. Due to the small number of patients and the failure to determine a cut-off value with acceptable sensitivity and specificity using ROC analysis, the median values were chosen as the cut-off value. The patients were basically divided into two according to their median TMT (6.6 mm) or TMA (452 mm2) values, and survival analysis was performed with the Kaplan–Meier analysis. Results: The median TMT value was 6.6 mm, and the median TMA value was 452 mm2. The median overall survival (OS) was calculated as 25.8 months in patients with TMT < 6.6 mm, and 15.8 months in patients with TMT ≥ 6.6 mm (p = 0.29). The median overall survival (OS) of patients with TMA < 452mm2 was 26.3 months, and the group with TMA ≥ 452mm2 was 14.6 months (p = 0.06). The median disease-free survival was 18.3 months (%95 CI: 13.2–23.4) in patients with TMT < 6.6mm, while mDFS was 10.9 (%95 CI: 8.0–13.8) months in patients with TMT ≥ 6.6mm (p = 0.21). The median disease-free survival was found to be 21.0 months (%95 CI: 15.8–26.1) in patients with TMA < 452 mm2 and 10.5 months (%95 CI: 7.8–13.2) in patients with TMA ≥ 452 mm2 (p = 0.018). Conclusion: No association could be demonstrated between TMT or TMA and OS of GBM patients. In addition, the median DFS was found to be longer in patients with low TMA. There is an unmet need to determine the optimal method of sarcopenia in GBM patients.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007;114(2):97-109. https://doi.org/10.1007/s00401-007-0243-4
- 2. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8):1231-1251. https://doi.org/10.1093/neuonc/noab106
- 3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005;352(10):987-996. https://doi.org/10.1056/ NEJMoa043330
- 4. Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurologica Scandinavica. 2010;122(3):159- 167. https://doi.org/10.1111/j.1600-0404.2010.01350.x
- 5. Chindapasirt J Sarcopenia in Cancer Patients. Asian Pacific Journal of Cancer Prevention. 2015;16(18):8075-8077. https:// doi.org/10.7314/apjcp.2015.16.18.8075
- 6. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical Cancer Research. 2009;15(8):2920-2926. https://doi.org/10.1158/1078-0432.Ccr- 08-2242
- 7. Kamarajah SK, Bundred J, Tan BHL Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(1):10-22. https://doi.org/10.1007/s10120-018-0882-2
- 8. Heymsfield SB, Adamek M, Gonzalez MC, Jia G, Thomas DM Assessing skeletal muscle mass: historical overview and state of the art. Journal Cachexia Sarcopenia Muscle. 2014;5(1):9-18. https://doi.org/10.1007/s13539-014-0130-5
- 9. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. Journal of Applied Physiology. (1985). 2004;97(6):2333-2338. https://doi.org/10.1152/japplphysiol.00744.2004
- 10. Swartz JE, Pothen AJ, Wegner I, Smid EJ, Swart KM et al. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncology. 2016;62:28-33. https://doi.org/10.1016/j. oraloncology.2016.09.006
- 11. Leitner J, Pelster S, Schöpf V, Berghoff AS, Woitek R et al. High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PloS One. 2018;13(11):e0207849. https://doi.org/10.1371/ journal.pone.0207849
- 12. Ranganathan K, Terjimanian M, Lisiecki J, Rinkinen J, Mukkamala A et al. Temporalis muscle morphomics: the psoas of the craniofacial skeleton. Journal of Surgical Research. 2014;186(1):246-252. https://doi.org/10.1016/j.jss.2013.07.059
- 13. Yesil Cinkir H, Colakoglu Er H Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme? Asia-Pacific Journal of Clinical Oncology. 2020;16(5):e223-e227. https://doi.org/10.1111/ajco.13369
- 14. An G, Ahn S, Park JS, Jeun SS, Hong YK Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma. Journal of Cancer Research and Clinical Oncology. 2021;147(3):901-909. https:// doi.org/10.1007/s00432-020-03386-5
- 15. Hsieh K, Hwang ME, Estevez-Inoa G, Save AV, Saraf A et al. Temporalis muscle width as a measure of sarcopenia correlates with overall survival in patients with newly diagnosed glioblastoma. Journal of Radiation Oncology. 2019;8(4):379- 387. https://doi.org/10.1007/s13566-019-00408-9
- 16. Go SI, Park MJ, Song HN, Kang MH, Park HJ et al. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Supportive Care in Cancer. 2016;24(5):2075-2084. https://doi. org/10.1007/s00520-015-2997-x
- 17. Antoun S, Borget I, Lanoy E Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Current Opinion in Supportive and Palliative Care. 2013;7(4):383-389. https://doi.org/10.1097/ spc.0000000000000011
- 18. Souza BU, Souza NCS, Martucci RB, Rodrigues VD, Pinho NB et al. Factors Associated with Sarcopenia in Patients with Colorectal Cancer. Nutrition and Cancer. 2018;70(2):176-183. https://doi.org/10.1080/01635581.2018.1412480
- 19. Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U et al. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. European Radiology. 2017;27(8):3167-3173. https://doi.org/10.1007/ s00330-016-4707-6
- 20. Hasegawa Y, Yoshida M, Sato A, Fujimoto Y, Minematsu T et al. Temporal muscle thickness as a new indicator of nutritional status in older individuals. Geriatrics & Gerontology International. 2019;19(2):135-140. https://doi.org/10.1111/ ggi.13570
- 21. Liu F, Xing D, Zha Y, Wang L, Dong W et al. Predictive Value of Temporal Muscle Thickness Measurements on Cranial Magnetic Resonance Images in the Prognosis of Patients With Primary Glioblastoma. Frontiers in Neurology. 2020;11:523292. https:// doi.org/10.3389/fneur.2020.523292
- 22. Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. European Journal of Pediatrics. 2020;179(5):839-847. https://doi.org/10.1007/ s00431-019-03556-9
- 23. Guven DC, Aksun MS, Cakir IY, Kilickap S, Kertmen N The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme. Future Oncology (London, England). 2021;17(32):4405-4413. https://doi.org/10.2217/fon-2021-0681
- 24. Furtner J, Weller M, Weber M, Gorlia T, Nabors B et al. Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials. Clinical Cancer Research. 2022;28(1):129-136. https:// doi.org/10.1158/1078-0432.Ccr-21-1987
- 25. Hasegawa Y, Yoshida M, Sato A, Fujimoto Y, Minematsu T et al. Temporal muscle thickness as a new indicator of nutritional status in older individuals. Geriatrics & Gerontology International. 2019;19(2):135-140
- 26. Steindl A, Leitner J, Schwarz M, Nenning KH, Asenbaum U et al. Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation. Journal of Clinical Medicine. 2020;9(5). https://doi.org/10.3390/ jcm9051272
- 27. Schaap LA, Pluijm SM, Deeg DJ, Visser M Inflammatory markers and loss of muscle mass (sarcopenia) and strength. American Journal of Medicine. 2006;119(6):526.e529-517. https://doi.org/10.1016/j.amjmed.2005.10.049
- 28. Li W, Liu Q, Tang Y Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Scientific Reports. 2017;7:40426. https://doi. org/10.1038/srep40426
- 29. Cummings M, Merone L, Keeble C, Burland L, Grzelinski M et al. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. British Journal of Cancer. 2015;113(2):311-320. https://doi.org/10.1038/ bjc.2015.200
- 30. Aslan V, Kılıç ACK, Sütcüoğlu O, Eraslan E, Bayrak A et al. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma. Urologic Oncology. 2022;40(11):494.e491-494.e410. https://doi.org/10.1016/j.urolonc.2022.07.018
| APA | sutcuoglu o, Erdal Z, akdogan o, CELTIKCI E, Ozdemir N, Ozet A, UCAR M, Yazıcı O (2023). The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. , 420 - 431. 10.55730/1300-0144.5599 |
| Chicago | sutcuoglu osman,Erdal Zeynep Sezgi,akdogan orhun,CELTIKCI EMRAH,Ozdemir Nuriye,Ozet Ahmet,UCAR MURAT,Yazıcı Ozan The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. (2023): 420 - 431. 10.55730/1300-0144.5599 |
| MLA | sutcuoglu osman,Erdal Zeynep Sezgi,akdogan orhun,CELTIKCI EMRAH,Ozdemir Nuriye,Ozet Ahmet,UCAR MURAT,Yazıcı Ozan The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. , 2023, ss.420 - 431. 10.55730/1300-0144.5599 |
| AMA | sutcuoglu o,Erdal Z,akdogan o,CELTIKCI E,Ozdemir N,Ozet A,UCAR M,Yazıcı O The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. . 2023; 420 - 431. 10.55730/1300-0144.5599 |
| Vancouver | sutcuoglu o,Erdal Z,akdogan o,CELTIKCI E,Ozdemir N,Ozet A,UCAR M,Yazıcı O The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. . 2023; 420 - 431. 10.55730/1300-0144.5599 |
| IEEE | sutcuoglu o,Erdal Z,akdogan o,CELTIKCI E,Ozdemir N,Ozet A,UCAR M,Yazıcı O "The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective." , ss.420 - 431, 2023. 10.55730/1300-0144.5599 |
| ISNAD | sutcuoglu, osman vd. "The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective". (2023), 420-431. https://doi.org/10.55730/1300-0144.5599 |
| APA | sutcuoglu o, Erdal Z, akdogan o, CELTIKCI E, Ozdemir N, Ozet A, UCAR M, Yazıcı O (2023). The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. Turkish Journal of Medical Sciences, 53(1), 420 - 431. 10.55730/1300-0144.5599 |
| Chicago | sutcuoglu osman,Erdal Zeynep Sezgi,akdogan orhun,CELTIKCI EMRAH,Ozdemir Nuriye,Ozet Ahmet,UCAR MURAT,Yazıcı Ozan The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. Turkish Journal of Medical Sciences 53, no.1 (2023): 420 - 431. 10.55730/1300-0144.5599 |
| MLA | sutcuoglu osman,Erdal Zeynep Sezgi,akdogan orhun,CELTIKCI EMRAH,Ozdemir Nuriye,Ozet Ahmet,UCAR MURAT,Yazıcı Ozan The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. Turkish Journal of Medical Sciences, vol.53, no.1, 2023, ss.420 - 431. 10.55730/1300-0144.5599 |
| AMA | sutcuoglu o,Erdal Z,akdogan o,CELTIKCI E,Ozdemir N,Ozet A,UCAR M,Yazıcı O The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. Turkish Journal of Medical Sciences. 2023; 53(1): 420 - 431. 10.55730/1300-0144.5599 |
| Vancouver | sutcuoglu o,Erdal Z,akdogan o,CELTIKCI E,Ozdemir N,Ozet A,UCAR M,Yazıcı O The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. Turkish Journal of Medical Sciences. 2023; 53(1): 420 - 431. 10.55730/1300-0144.5599 |
| IEEE | sutcuoglu o,Erdal Z,akdogan o,CELTIKCI E,Ozdemir N,Ozet A,UCAR M,Yazıcı O "The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective." Turkish Journal of Medical Sciences, 53, ss.420 - 431, 2023. 10.55730/1300-0144.5599 |
| ISNAD | sutcuoglu, osman vd. "The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective". Turkish Journal of Medical Sciences 53/1 (2023), 420-431. https://doi.org/10.55730/1300-0144.5599 |
